LILRB2 Overview
Molecule Name
Leukocyte immunoglobulin-like receptor subfamily B member 2
Synonyms
LILRB2,ILT4,LIR2,MIR10,CD85d
Drug Development Progress
Drugs in Clinical Trials11
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Leukocyte immunoglobulin-like receptor 2，CD85 antigen-like family member D，Immunoglobulin-like transcript 4，ILT-4，Monocyte/macrophage immunoglobulin-like receptor 10，MIR-10，CD_antigen: CD85d，LILRB2，Leukocyte Immunoglobulin Like Receptor B2，Leucocyte Ig-Like Receptor B2，MIR10，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 2，Ig-Like Transcript 4，Myeloid Inhibitory Receptor 10，CD85d Antigen，ILT4，LIR2，CD85d，LIR-2，LIRB2
Background
Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
LILRB2 Product List
You Have Viewed 0 Of 0 Results
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| LILRB2 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
- Project Name
- LILRB2 mAb - 01
- Project Stage
- PCC
- Molecule Type
- Monoclonal
- Molecule Source
- Humanized Mouse
- Disease Area
- Solid Tumor
- Indication
- Solid tumor